Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVATE: Chronic Kidney Disease Adaptive Platform Trial Investigating Finerenone
2024-520253-21-00Phase 3Authorised
- Sponsor
- The George Institute for Global Health
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised trial of finerenone in chronic kidney disease (CKD) (3 arms), sponsored by The George Institute for Global Health. Primary endpoint: Chronic eGFR slope from week 4 to week 104. Planned start Jun 2025; status: authorised.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-520253-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520253-21-00.